Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial64

File Visits

Downloads
VERSION EDITOR.pdf12

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial44

Number of downloads in the range

Downloads
VERSION EDITOR.pdf1

Views

Views
January 20256
February 20251
March 202519
April 20252
May 20253
June 20257
July 20256
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • January 2025
    0
  • February 2025
    0
  • March 2025
    0
  • April 2025
    1
  • May 2025
    0
  • June 2025
    0
  • July 2025
    0
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore19
United States6
Brazil5
Hong Kong4
Germany2
Italy2
United Arab Emirates2
Austria1
Spain1
Ethiopia1
 

Top countries by downloads

Downloads
Spain1
 

Top cities views

Views
Hong Kong4
Los Angeles2
Addis Ababa1
Caxias do Sul1
Council Bluffs1
Guanajuato City1
Jackson1
Lavras1
Natal1
Nuremberg1
 

Top cities by downloads

Downloads